Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.81 USD | -0.56% | -4.45% | -20.63% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- This company will be of major interest to investors in search of a high dividend stock.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company does not generate enough profits, which is an alarming weak point.
- With an expected P/E ratio at 264.33 and 139.11 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Specialized REITs
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-20.63% | 578M | C | ||
+12.93% | 60.89B | A- | ||
+0.02% | 20.14B | A- | ||
-2.17% | 13.63B | A | ||
+9.07% | 8.26B | B | ||
-4.76% | 6.21B | B- | ||
+10.10% | 3.56B | C- | ||
+3.85% | 3.43B | C+ | ||
-11.47% | 2.86B | B+ | ||
+19.77% | 2.9B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- GMRE Stock
- Ratings Global Medical REIT Inc.